Kim Brazzell

Biography

Dr. Kim Brazzell, Ph.D. has been Chief Medical Officer at Kala Pharmaceuticals, Inc. since February 2013. Dr. Brazzell has been Chief Medical Officer of Mimetogen Pharmaceuticals Inc. since January 5, 2012. Dr. Brazzell has more than 25 years of experience in the ophthalmic pharmaceutical industry to Mimetogen. Previously, he served several executive positions at Inspire Pharmaceuticals, including Executive Vice President, Medical and Scientific Affairs, Executive Vice President and Head, Ophthalmology Business and Senior Vice President of Ophthalmic Research and Development. Prior to joining Inspire, he served as Global Head of Clinical R&D and Senior Vice President, U.S. R&D, of Novartis Ophthalmics. He has extensive experience in the discovery and development of multiple successful ophthalmic products including Visudyne(R) , Zaditor(R) , RESCULA(R) and Betoptic S(R). Along with managing the global clinical R&D group for Novartis Ophthalmics, Dr. Brazzell built and managed the U.S.-based R&D group for Ciba Vision Ophthalmics. He served Vice President of R&D at Ciba Vision Ophthalmics and served as Associate Director of R&D at Alcon Laboratories, Inc. He serves as a Member of Advisory Board at Brickell Biotech, Inc. Dr. Brazzell received a B.S. in Pharmacy and a Ph.D. in Pharmaceutical Science from the University of Kentucky. 

Research Interest

Vision Ophthalmics,Pharmaceuticals